Antibiotic Susceptibility Profiles for Group B Streptococci Isolated from Neonates, 1995-1998 | Zendy

Feng Lin | Zendy; Parvin H. Azimi | Zendy; Leonard E. Weisman | Zendy; Joseph B. Philips | Zendy; Joan A. Regan | Zendy; Penny Clark | Zendy; G G Rhoads | Zendy; John D. Clemens | Zendy; James Troendle | Zendy; E Pratt | Zendy; Ruth A. Brenner | Zendy; V J Gill | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antibiotic Susceptibility Profiles for Group B Streptococci Isolated from Neonates, 1995-1998

Author(s) -

Feng Lin,

Parvin H. Azimi,

Leonard E. Weisman,

Joseph B. Philips,

Joan A. Regan,

Penny Clark,

G G Rhoads,

John D. Clemens,

James Troendle,

E Pratt,

Ruth A. Brenner,

V J Gill

Publication year - 2000

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/313936

Subject(s) - erythromycin , clindamycin , penicillin , cefotaxime , microbiology and biotechnology , antibiotics , medicine , streptococcus , chloramphenicol , vancomycin , drug resistance , streptococcaceae , biology , bacteria , staphylococcus aureus , genetics

Antibiotic susceptibility profiles were analyzed for 119 invasive and 227 colonizing strains of group B streptococci isolated from neonates at 6 US academic centers. All strains were susceptible to penicillin, vancomycin, chloramphenicol, and cefotaxime. The rate of resistance to erythromycin was 20.2% and to clindamycin was 6.9%. Resistance to erythromycin increased in 1997. Type V strains were more resistant to erythromycin than were type Ia (P=.003) and type Ib (P=.004) strains and were more resistant to clindamycin than were type Ia (P<.001), type Ib (P=.01), and type III (P=.001) strains. Resistance rates varied with geographic region: in California, there were high rates of resistance to erythromycin and clindamycin (32% and 12%, respectively), and low rates in Florida (8.5% and 2.1%, respectively). Penicillin continues to be the drug of choice for treatment of group B streptococcus infection. For women who are penicillin intolerant, however, the selection of an alternative antibiotic should be guided by contemporary resistance patterns observed in that region.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research